NR-55420来自SARS相关冠状病毒2的刺突糖蛋白S1结构域,带有C末端组氨酸标签的P681H变体,来自HEK293细胞的重组(蛋白质）
产品图片
货号/SKU
NR-55420
货号/规格
EA
库存与交货期
3-8周
人民币价格
14000
试剂海关审批
A/B级风险物质只能直接使用人购买并持有实验室有效资质，其它询客服确认
国外采购
支持/部分限制一年内购买数量
厂牌
BEI Resources(ATCC)
产品基础信息
生物安全等级建议分类：美国、1
产品描述信息
NR-55420?? Spike Glycoprotein S1 Domain from SARS-Related Coronavirus 2, P681H Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells(Proteins)|SARS-Related Coronavirus 2|Spike Glycoprotein S1 Domain from SARS-Related Coronavirus 2, P681H Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells|-20°C or colder|ACROBiosystemsAcknowledgment for publications should read “The following reagent was obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein S1 Domain from SARS-Related Coronavirus 2, P681H Variant with C-Terminal Histidine Tag, Recombinant from HEK293 Cells, NR-55420.”|Quantity limit per order for this item is 1. This item can be ordered twice a year. Orders over this limit will be sent to NIAID for approval before shipment.
A recombinant form of the spike (S) glycoprotein S1 domain from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), P681H variant was produced by transient transfection in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55420 lacks the signal sequence, contains 670 residues of the SARS-CoV-2 S glycoprotein (amino acid residues V16 to R685) and features a C-terminal poly-histidine tag. NR-55420 is a variant of SARS-CoV-2 which contains the P681H mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55420 has a theoretical molecular weight of 76,900 daltons. The crystal structure for the wild-type S glycoprotein from SARS-CoV-2 has been solved at 2.8 ? resolution (PDB: 6VXX).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The P681H mutation was identified in the SARS-CoV-2 variant (known as 20B/501Y.V1, VOC 202012/01 or B.1.1.7 lineage) which emerged in the United Kingdom. P681 is part of the S1/S2 proteolytic cleavage site for furin proteases, and the mutation P681H results in increased cleavage efficiency and may alter antibody recognition sites.
The biological activity of NR-55420 was measured by its binding ability in a functional ELISA, in which immobilized NR-55420 at 2 ?g per mL (100 ?L per well) can bind human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257); the linear range is 0.1 to 3 ng per mL.
Each vial contains approximately 100 ?g of purified recombinant protein lyophilized in phosphate-buffered saline, pH 7.4 and 10% trehalose.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
A recombinant form of the spike (S) glycoprotein S1 domain from severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), P681H variant was produced by transient transfection in human embryonic kidney HEK293 cells and purified by affinity chromatography. NR-55420 lacks the signal sequence, contains 670 residues of the SARS-CoV-2 S glycoprotein (amino acid residues V16 to R685) and features a C-terminal poly-histidine tag. NR-55420 is a variant of SARS-CoV-2 which contains the P681H mutation in the S glycoprotein as compared to the SARS-CoV-2 reference sequence (GenPept: QHD43416). NR-55420 has a theoretical molecular weight of 76,900 daltons. The crystal structure for the wild-type S glycoprotein from SARS-CoV-2 has been solved at 2.8 ? resolution (PDB: 6VXX).
The S glycoprotein mediates viral binding to the host angiotensin converting enzyme 2 (ACE2). This protein forms a trimer, and when bound to a host receptor allows fusion of the viral and cellular membranes. The P681H mutation was identified in the SARS-CoV-2 variant (known as 20B/501Y.V1, VOC 202012/01 or B.1.1.7 lineage) which emerged in the United Kingdom. P681 is part of the S1/S2 proteolytic cleavage site for furin proteases, and the mutation P681H results in increased cleavage efficiency and may alter antibody recognition sites.
The biological activity of NR-55420 was measured by its binding ability in a functional ELISA, in which immobilized NR-55420 at 2 ?g per mL (100 ?L per well) can bind human ACE2 protein (Fc tag) (ACROBiosystems AC2-H5257); the linear range is 0.1 to 3 ng per mL.
Each vial contains approximately 100 ?g of purified recombinant protein lyophilized in phosphate-buffered saline, pH 7.4 and 10% trehalose.
Additional information and tools are available at ViPR (Virus Pathogen Resource).
主要内容
此项目的每个订单数量限制为1.此商品每年可订购两次.此限制的订单将在发货前发送到NIAID批准.
来自严重急性呼吸综合征相关的冠状病毒2（SARS-COV-2）的穗状花序的重组形式，通过人胚胎肾HEK293细胞的瞬时转染并通过亲和色谱法纯化，产生P681H变体. NR-55420缺乏信号序列，含有670个残基的SARS-COV-2S糖蛋白（氨基酸残基V16至R685），并具有C末端多组氨酸标签. NR-55420是SARS-COV-2的变体，其含有与SARS-COV-2参考序列（Genpept：）. NR-55420具有76,900道尔顿的理论分子量.来自SARS-COV-2的野生型糖蛋白的晶体结构已经解决了2.8埃分辨率（PDB： 6VXX ）.
S糖蛋白介导与宿主血管紧张素转化酶2（ACE2）的病毒结合.该蛋白质形成三聚体，并且当与宿主受体结合时，允许融合病毒和细胞膜.在英国出现的SARS-COV-2变体中鉴定了P681H突变（称为20B / 501Y.V1，VOC 202012/01或B.1.1.7谱系）. P681是Furin蛋白酶S1 / S2蛋白水解切割位点的一部分，突变P681H导致裂解效率增加，并且可以改变抗体识别位点.
通过其功能ELISA的结合能力测量NR-55420的生物活性，其中固定的NR-55420在每毫升（每孔100μl）中为2μg（100μl）可以结合人ACE2蛋白（FC标签）（Acrobiosystems AC2-H5257） ;线性范围为每mL 0.1至3 ng.
每个小瓶在磷酸盐缓冲盐水，pH 7.4和10％海藻糖中含有大约100μg纯化的重组蛋白.
vipr （病毒病原体资源）提供了附加信息和工具.
厂牌介绍
BEI Resources 由美国国家过敏和传染病研究所 ( NIAID )成立，旨在为研究 A、B 和 C 类优先病原体、新兴传染病病原体、非病原微生物和其他相关微生物材料提供试剂、工具和信息到研究界。BEI Resources 获取、验证和生产科学家进行基础研究和开发改进的诊断测试、疫苗和疗法所需的试剂。通过将这些功能集中在 BEI Resources 中，可以监控科学界对这些材料的访问和使用，并确保试剂的质量控制。
除了为传染病界提供材料外，BEI Resources 还鼓励和支持研究人员和机构的材料存放。使用 BEI Resources存放材料对研究人员和研究社区有许多优势，包括安全存储、社区访问和分发；同时保护存款人的知识产权。只要有需要，BEI 资源库将作为研究人员的资源进行维护。您在 BEI Resources 的存款是一项有助于未来研究的长期投资。
BEI Resources 自 2003 年起由美国典型培养物保藏中心 (ATCC) 根据合同管理。2016 年 5 月， ATCC获得了一份为期七年的继续管理 BEI Resources的合同。合同范围已扩大到更全面的研究目录材料，包括由其他政府支持的研究项目存放的材料，将提供给生物防御和新兴传染病科学界。真菌、寄生虫、载体和其他相关材料已添加到现有的细菌、病毒和毒素试剂中，涵盖 NIAID A、B 和 C 类优先病原体和 NIAID 指定的新发传染病病原体和生物。
品牌标识
可能感兴趣的内容
2022-03-31
2022-04-01
2021-12-21
2021-12-13
2021-12-21
2024-05-19
2022-04-01
2024-05-19
2021-12-02
2022-04-01
2024-05-19
2022-04-01
2019-05-08
2021-12-21
2024-06-03